食管疾病2024，Vol.6Issue(3)：217-223,7.DOI:10.15926/j.cnki.issn2096-7381.2024.03.010
新辅助免疫治疗联合化疗对可切除局部晚期食管癌患者的回顾性分析
Retrospective Analysis of Neoadjuvant Immunotherapy Combined with Chemotherapy in Patients with Resectable Locally Advanced Esophageal Cancer
李培豪 1郎保平 2张典 2张超 2薛金良 2尚锴2
作者信息
- 1. 新乡医学院,河南新乡,453003||郑州大学附属洛阳市中心医院胸外科,河南洛阳,471000
- 2. 郑州大学附属洛阳市中心医院胸外科,河南洛阳,471000
- 折叠
摘要
Abstract
Objective To explore the clinical efficacy,safety,and impact on surgery of camrelizumab combined with docetaxel+nedaplatin for neoadjuvant therapy in patients with stage T3～4a esophageal cancer.Methods The clinical data of 56 patients with locally advanced esophageal cancer who received neoadjuvant therapy in conjunction with radical esophageal cancer surgery admitted to our hospital from Janu-ary 2019 to June 2022 were retrospectively analyzed.The patients were divided into two groups according to different treatments for different years of hospitalization:the combination group(n=26)applied pre-operative chemotherapy with camrelizumab combined with docetaxel+nedaplatin,and the chemotherapy group(n=30)applied pre-operative chemotherapy with docetaxel+nedaplatin.Adverse reactions during neo-adjuvant therapy,impacts on surgery,perioperative indicators,imaging changes and pathologic outcomes were compared between the two groups.Results The pathological complete remission rate of patients in the com-bined group was 23.08％,while that of the control group was 3.33％,the difference was statistically signifi-cant(P＜0.05).The complete remission rate,objective remission rate,and disease control rate of patients in the combined group were higher than those in the chemotherapy group(P＜0.05).There was no statistically significant difference in the incidence of adverse re-actions between the two groups of patients during neoadjuvant therapy(P＞0.05).There was no statis-tically significant difference in perioperative indicators and postoperative complications between the two groups of patients(P＞0.05).There was no statis-tically significant difference in the short-term progression free survival rate and overall survival rate between the two groups of patients(P＞O.05).Conclusion Conclusion Neoadjuvant camrelizumab combined with docetaxel+nedaplatin chemotherapy for T3～T4a stage esophageal cancer is safe and feasible,without increasing the incidence of treatment-related adverse reactions,and shows a good pathological remission rate compared with chemotherapy alone.关键词
食管癌/免疫治疗/新辅助治疗Key words
esophageal cancer/immunotherapy/neoadjuvant therapy分类
医药卫生引用本文复制引用
李培豪,郎保平,张典,张超,薛金良,尚锴..新辅助免疫治疗联合化疗对可切除局部晚期食管癌患者的回顾性分析[J].食管疾病,2024,6(3):217-223,7.
